At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 29 enrolled
Drug / intervention
sirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Evaluate the Safety and Efficacy of Mycophenolate Sodium (Myfortic®) in Combination With Sirolimus (Rapamune®) in Stable Renal Allograft Recipients
California Pacific Medical Center Research Institute·interventional·Posted Jul 11, 2008·Updated Oct 27, 2020
In Brief
A Phase 4 clinical trial evaluating sirolimus for Renal Transplantation. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplantation
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedJul 2008
Primary CompletionNov 2010
TodayJul 2026
First PostedJul 11, 2008
Enrollment StartMay 1, 2007
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.0 years ago
Interventions
sirolimusdrug
Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.